IGM Biosciences, Inc. (IGMS)
| Market Cap | 2.40B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -115.25M |
| Shares Out | 33.37M |
| EPS (ttm) | -3.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133,196 |
| Open | 73.05 |
| Previous Close | 74.82 |
| Day's Range | 71.37 - 74.78 |
| 52-Week Range | 42.00 - 133.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 103.00 (+39.9%) |
| Est. Earnings Date | Nov 8, 2021 |
About IGMS
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L...
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for IGMS stock is "Buy." The 12-month stock price forecast is 103.00, which is an increase of 39.87% from the latest price.
News
IGM Biosciences to Participate in Three Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...
IGM Biosciences Announces Second Quarter 2021 Financial Results and Provides Corporate Update
– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 –
IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D.
MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...
5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021
These biotech stocks could have great long-term potential.
IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Natu...
Company Expects to Advance First Intranasally Administered IgM Antibody, IGM-6268, into the Clinic in Third Quarter of 2021 Company Expects to Advance First Intranasally Administered IgM Antibody, IGM-6...
8 Stocks With The Highest Short Interest
Traders often look at short interest to get a sense of how many people are bearish on a stock and how strong the possibility of a short squeeze is. But simply looking at the size of the outstanding shor...
IGM Biosciences Announces First Quarter 2021 Financial Results and Provides Corporate Update
– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 –
Resolutions at the Annual General Meeting in Medivir on 5 May 2021
HUDDINGE, Sweden, May 5, 2021 /PRNewswire/ -- Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director The annual general meet...
IGM Biosciences to Present at the Truist Securities Life Sciences Summit
MOUNTAIN VIEW, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...
Medivir to participate at the Kempen Life Sciences Conference
STOCKHOLM, April 20, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will participate at the virtual meeting Kempen Life Sciences Conference - 2021 Thematic Vi...
Medivir appoints Magnus Christensen as interim CEO
STOCKHOLM, April 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its Board of Directors appoints Magnus Christensen, the company's CFO, as interim CEO of Medivir. Magnu...
Medivir 2020 Annual Report published
STOCKHOLM, April 6, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2020 now is available at the company's website: www.medivir.com. In the spring of ...
Number of shares and votes in Medivir
STOCKHOLM, March 31, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during March 2021 as a result of the previously a...
IGM Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
– Recommended Phase 2 Dose for IGM-2323 Expected in 2021 –
Last patient with liver cancer included in the monotherapy part of Medivir's phase Ib study with MIV-818
STOCKHOLM, March 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the last patient with advanced liver cancer has been included in the first part of the phase Ib study w...
IGM Biosciences to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast o...
MOUNTAIN VIEW, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...
Changes in Medivir's management and Board of Directors
STOCKHOLM, March 22, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that Yilmaz Mahshid leaves the position as CEO of Medivir. The nomination committee proposes that he is elec...
Resolution at the extraordinary general meeting in Medivir on 11 March 2021
HUDDINGE, Sweden, March 11, 2021 /PRNewswire/ -- Resolution on a directed issue of shares The extraordinary general meeting in Medivir Aktiebolag (publ) on 11 March 2021 resolved, in accordance with the...
Medivir to present at the H.C. Wainwright Global Life Sciences Conference
STOCKHOLM, March 8, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright Global Life Sciences Conference, March 9...
Number of shares and votes in Medivir
STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during February 2021 as a result of the previously...
IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day
MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...
Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant
STOCKHOLM, Jan. 12, 2021 /PRNewswire/ -- Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences, Inc. (Nasdaq...
IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant
- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors - - IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors -
IGM Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...
This Biotech Skyrocketed 84% in 2 Days, But Is It Warranted?
Short squeezes don't typically live up to their expectations.